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Abstract 
For melanoma patients with metastatic, NRAS-mutant tumors, treatment options are limited. 
However, the recent FDA approval of immune checkpoint inhibitors (e.g. PD-1 and PD-L1 
inhibitors) has brought new hope these patients. While responses to these drugs are often durable 
and robust, only a subset of melanoma patients will benefit from therapy. Morevoer, biomarkers 
to accurately predict which patients will respond are desperately needed. Recent studies have 
linked loss of the Liver Kinase B1 (LKB1) tumor suppressor gene to melanoma metastasis, as 
well as suggested a potential relationship between LKB1 and PD-L1 expression. Thus, LKB1 
may be useful as a biomarker for predicting patient response to immune checkpoint inhibitors. 
Here, we created NRAS-mutant melanoma cell lines with differing LKB1 status to evaluate the 
role of this protein in migration. We find that restoration of LKB1 inhibits cellular migration. 
Using genetically engineered mouse models, we confirm this finding by showing that the loss of 
Lkb1, in combination with NRAS-mutation and ultraviolet (UV) light exposure, promotes 
metastatic melanoma progression. Finally, we discovered that restoration of kinase-deficient or 
proficient LKB1 activity in several melanoma cell lines leads to increases in PD-L1 expression. 
Together these data provide evidence that LKB1 loss may be a marker of metastatic progression 
and of resistance to immune checkpoint inhibitor therapies.  
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Introduction 
In 2016, the American Cancer Society predicts that 76,380 new melanomas will be diagnosed 
and 10,130 people will succumb to the disease [1]. In situ and early-stage melanomas are 
curable; however, metastatic melanoma is one of the deadliest cancer types, with a 5-year 
survival rate of only 17%[1]. Although the incidence of metastatic melanoma has steadily 
increased over recent decades, it can be expected to rise even further in upcoming years due to 
the aging U.S. population. For a long time, treatment options for metastatic melanoma patients 
were limited, and due to the rapidity in which melanomas metastasize, surgical excision was 
rarely curative. In fact, as of 2011, the US Food and Drug Administration had approved only two 
drugs for the treatment of advanced metastatic melanoma: decarbazine, a chemotherapy which 
Underiner 2 
was approved in 1975, and high-dose interleukin-2 (IL-2), an immunological therapy which was 
approved in 1998[2] [2]. These drugs showed limited success in patients, with decarbazine 
shrinking tumors 12.5% of the time[3] and IL-2 being curative in only 4% of patients[4]. 
Furthermore, response to these drugs was often limited, as many tumors grew resistant[5].   
 
Fortunately, in the last five years, multiple efficacious drugs were approved for the treatment of 
melanoma. These new therapies can be divided into two categories: BRAF inhibitors and 
immune checkpoint inhibitors. BRAF, which is mutated in approximately 50% of melanoma 
patients, is a kinase which activates the downstream ERK pathway through phosphorylation of 
MEK, thereby promoting cell proliferation and survival. BRAF-mutant inhibitor therapies, such 
as vemurafenib and dabrafenib, have high response rates in melanoma patients and improve 
patient survival [6]. However, limitations remain. For example, treatment durability is a problem, 
as tumor cells rapidly develop resistance to BRAF inhibitors[6]. Additionally, though BRAF 
mutations are found in many melanoma patients, approximately one third of patients harbor 
mutually exclusive mutations in the proto-oncogene, NRAS.  These patients do not respond to 
BRAF inhibitor therapies. Checkpoint inhibitor therapies target the immune system, leading to 
enhanced tumor cell recognition and elimination. In the human body, all cells contain MHC 
Class I proteins that display antigens on the surface of the cell for recognition by the immune 
system. Cancer cells, however, produce many mutated proteins, and therefore may display 
abnormal antigens, called neoantigens, on the surface of the cell. These neoantigens enable T-
cells to recognize the tumor cell as foreign and initiate a response against them. Tumor cells, 
however, have found a way to evade immune recognition, through complex interactions between 
the Programmed Death 1 (PD-1) receptor on T cells and Programmed Death Ligand 1 (PD-L1) 
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on tumor cells (Fig. 1A). Checkpoint inhibitor therapies, such as pembrolizumab and nivolumab 
(PD-1 inhibitors), successfully in block the PD-L1-PD-1 interaction, thereby allowing the 
immune system to once again respond to neoantigens 
expressed on the tumor cell surface (Fig. 1B) [7]. Unlike 
chemotherapies and BRAF inhibitors, responses to immune 
checkpoint therapies appear more durable.  However, it is 
unknown why some patients respond to immunotherapy while 
others do not. Only a small subset of melanoma patients  (up 
to 40%) respond to approved checkpoint inhibitor therapies (ie. 
tumor regression or stabilization of disease), yet more than half 
of these individuals achieve long-term responses lasting more 
than one year[8]. Since these therapies can be toxic and costly, robust biomarkers are desperately needed to predict the 
approximately 40% of patients that will respond. There are 
currently no targeted agents approved to treat NRAS-mutant 
tumors, which are notoriously aggressive. To increase the cure 
rate of these patients, two options should be considered: 
prevent metastasis or improve responses to immune checkpoint 
inhibitor therapies, such PD-L1 inhibitors.  
 
Several studies show that mutations in the Liver Kinase B1 (LKB1) tumor suppressor gene are 
linked to metastatic potential in lung adenocarcinomas[9], breast cancers[10], and 
melanoma[11]. A more recent study also demonstrates that the loss of LKB1 expression 
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Figure 1,  Tumor cells evade the 
immune system through PD-L1 
expression. A, Diagram illustrating 
a mechanism of immune system 
evasion in tumor cells. Tumor cells 
bind to T-cells and deactivate them 
via PD-1-PD-L1 interaction. B, 
Diagram demonstrating the 
mechanism by which checkpoint 
inhibitor therapies can promote 
normal immune response to tumor 
cells. These immunotherapy drugs 
bind to the PD-1 receptor or PD-L1 
ligand, inhibiting the tumor cells 
from deactivating the T-cells.  
Image loosely based on figure by 
Guha et al, (2014). 
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promotes metastasis in a KRASG12D-driven murine melanomas[12]. However, as NRAS 
mutations vastly outweigh the number of KRAS mutations in human melanoma, the clinical 
relevance of that study is unclear. In comparison to KRAS mutations, which are present in 
roughly 2% of human melanomas, NRAS-driven tumors are far more representative, occurring in 
up to 30% of lesions[13]. Consequently, a portion of the present study focused on elucidating the 
role of LKB1 and its kinase activity in the metastasis of NRAS-driven melanoma, through both 
in vitro and in vivo models. As several lung cancer studies have also noted a correlation between 
LKB1 loss and elevated PD-L1 expression[14, 15], the present study also explored the 
relationship between LKB1 kinase function and PD-L1 expression in melanoma.  
 
 
Materials and Methods 
Generation of melanoma cell lines with differing LKB1 status 
In several LKB1-null murine melanoma cell lines (NL212, NL216, and NL145) as well as a 
human melanoma cell line (SK-MEL 103), LKB1 was reintroduced, either in a fully functional 
form (LKB1) or a kinase-dead version (LKB1-KD). LKB1 infection was also performed on one 
LKB1-proficient human melanoma cell line (SK-MEL 147. LKB1 and LKB1-KD lentivirus was 
generated via polyethylenimine (PEI) transfection of 293T cells with either pBABE FLAG-
LKB1 or FLAG LKB1-KD plasmids (2 μg), as well as the pCMV-VSV-G envelope (0.222 μg) 
and pUMVC packaging plasmids (1.176 μg). 16 μL of PEI transfection reagent (1 mg/mL) was 
added to the plasmids and then pipetted onto the host cells. Cells were incubated for 1 hour in 
serum-free media, after which full media was returned and changed the following day (day 2). 
On day 3, virus was collected from the transfected cells, the media was filtered to eliminate any 
293T cells, and frozen for future use.  
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Target cell lines were infected with 5 mL of viral media and 5 mL of growth media, along with 
10 μL of polybrene (10 mg/mL). Infection was repeated on day two to further increase 
transduction efficiency. Media was changed following each infection and cells were allowed to 
recover for two days, after which puromycin was added (according to drug optimization curves: 
30 μg/mL for murine lines, 10 μg/mL for human lines) to begin selection. Cells underwent 
selection for 5-7 days.  
 
Immunnoblot Analysis for LKB1 Detection 
Immunoblots were performed on protein samples from all generated cell lines to confirm the 
expression of LKB1. Cells were lysed using RIPA buffer and PMSF protease inhibitors (1:100), 
then sonicated. Protein concentration was measured via Bradford Assay. All blots were run on 
10% SDS-Page gels and transferred to 0.45 μm nitrocellulose membranes. Membranes were 
blocked in a solution of 1% cold water fish gelatin in phosphate-buffered saline, and incubated in 
anti-LKB1 antibody (1:1000; Cell Signaling Technology, Cat. #3050) overnight. After washing 
3x with Tris-buffered saline with 0.1% Tween-20 (Sigma), membranes were incubated in anti-
rabbit fluorescent secondary antibody (IRDye 800CW 1:20,000; Licor Cat.# 926-32211) for 45 
minutes. To control for variations in the amount of protein loaded, membranes were also blotted 
for β-actin (1:2500; Cell Signaling Technology, Cat. #4967). Membranes were imaged using the 
Li-Cor Odyssey CLx Imaging System and analyses were performed using Image Studio 
software.  
 
 
 
Underiner 6 
Migration Assays 
Migration assays (Figure 3A) were performed in the murine cell lines. First, 12-well plates were 
coated in collagen for 3 hours after which cells were seeded and grown to confluency. To 
eliminate the effects of cell proliferation and ensure only migration was being assessed, the cells 
were treated with mitomycin C for 8 hours (according to drug optimization curves: 5 μg/mL for 
the NL212 and NL216 lines, 1.5 μg/mL for the NL145 line). After the 8-hour mitomycin C 
treatment, a 1 mm scratch was created in a straight, vertical line across the dish using a 1000 μL 
sterile pipet tip. Media was changed to remove any floating cell debris, and a photograph was 
taken of the initial scratch at t=0h. Cells were permitted to migrate for 18 hours, after which 
another photograph was taken at t=18h. Using ImageJ software, the percentage of wound closure 
was determined. All migration assays were performed in biological triplicates to verify results. 
Statistical significance was determined by 1-way ANOVA analysis.  
 
PD-L1 flow cytometry  
LKB1-null, LKB1 re-expressing (WT), and LKB1-KD cell lines were individually seeded to 
reach a density of 50-60% in 20 hours. They were then lightly trypsinized, centrifuged for 3 
minutes at 1200 RPM to remove any dead cells, and counted using a Coulter Counter. 
Approximately 500,000 cells were aliquotted per tube and tubes were kept on ice throughout the 
remaining steps. Cells were centrifuged once more (3 minutes, 1200 RPM) and resuspended in 
fluorescence-activated cell sorting (FACS) buffer (5% BSA in PBS). PE-conjugated PD-L1 
antibody (Biolegend, Cat.# 124308) and PE-conjugated Isotype Control antibody (Biolegend, 
Cat.# 400636) were added to their respective tubes at a 1:100 concentration, and allowed to 
incubate for 45 minutes in the dark at 4°C. Cells were then washed three times with FACS 
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buffer, resuspended in cold PBS, and filtered through a 40 μm cell strainer to remove any cell 
clumps. Cells were then immediately analyzed using a FlowSight Flow Cytometer (EMD 
Millipore, Model # 100300). The PE fluorophore was measured using the 488 nm excitation 
laser, set to 560-595 nm (channel #3). Results were quantified using IDEAS software (EMD 
Millipore), with gates set so that isotype controls had ≤1% of cells marked positive. 
 
Murine Alleles and Husbandry Genetically engineered mouse models containing conditional knock-in (i.e. LSL-N-
RasQ61R[16, 17] and Rosa26-YFP[18]) and knock-out (i.e. p16L[19] and LKB1L[12]) alleles 
(Herein, referred to as TpLNR mice), were used to evaluate the relationship between UV 
exposure, Lkb1 loss, metastasis, and PD-L1 expression. TpLNR mice were compared to TpNR 
mice, which contain the same LSL-N-RasQ61R, Rosa26-YFP, and p16L conditional alleles but 
have a functional Lkb1 allele. Tyrosinase- CRE ERT2 was used to drive the expression of a 
4OHT-inducible CRE recombinase specifically in melanocytes. As shown in Figure 5A, in the 
conditional p16L allele, CRE recombination causes the excision of exon 1α, preventing the 
expression of p16INK4a but maintaining p19ARF. In the conditional LKB1L knock-out allele, CRE 
recombination results in the excision of exons 3-6. The LSL-N-rasQ61R and Rosa26-YFP alleles 
are knock-ins that conditionally expresses N-RASQ61R and YFP, respectively, upon removal of a 
transcriptional stop element (3xSTOP) by CRE-mediated recombination. Green arrowheads 
denote the location of loxP recognition sites, which are excised during CRE-medicated 
recombination.  All animal work was conducted in accordance with protocols approved by the 
Institutional Animal Care and Use Committee (IACUC) at the Ohio State University (IACUC 
protocol #2012A00000134).  
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Induction of CRE Recombinase via 4-OHT and UVB treatment 
To characterize the organs to which melanomas metastasize in mice lacking Lkb1 and further 
study the relationship between LKB1 and PD-L1, tumors were induced in four litters of 
TpLNQ61R mice. On postnatal days 1 and 2, pups were painted with 4-hydroxytamoxifen (25 
mg/mL) dissolved in dimethyl sulfoxide to stimulate CRE-ERT2 activity, leading to expression 
of NRASQ61R and loss of p16 and LKB1. On day 3, mice were split into ultra-violet (UV) 
exposure and non-exposure groups at a 3:1 ratio. Mice in the UV exposure group were exposed 
to 4.5 kJ/m2 UV radiation to evaluate the effect of UV radiation on metastasis in NRAS-driven, 
LKB1-deficient melanomas.  
 
Assessment of melanomas  
Each cohort of mice was checked twice weekly for the formation of new tumors. Once a new 
tumor was noted, tumor growth was assessed at least 5 times per week by digital caliper 
measurements of the tumor dimensions [width x length (mm)] until IACUC exclusion criteria for 
tumor burden or comorbidities were met. Necropsies were then performed and primary tumor 
and organs with potential macrometastases (commonly the tumor proximal lymph nodes and the 
spleen) were harvested. After formalin fixation and paraffin embedding, these tissues were 
evaluated for histological abnormalities, and stained for PD-L1. For analysis purposes, tumor 
growth was normalized to day 1 and linear regression models of tumor growth created using 
GraphPad Prism software. Analysis of melanoma-free survival, overall survival, tumor burden, 
and tumor growth rates were also performed with GraphPad Prism software. Gehan-Breslow-
Wilcoxon tests were performed for each experimental group to assess the statistical significance 
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of tumor-free survival; Mann-Whitney tests were used to determine the statistical significance of 
average tumor burden and linear regression of tumor growth between the groups.  
 
Results 
Generation of stable LKB1 and LKB1-KD cell lines via lentiviral transduction 
The loss of Lkb1 has 
been implicated in 
enhanced metastasis in 
KRAS-driven 
melanomas [12]; 
however, the role of this 
protein and its kinase activity 
has never been addressed in 
NRAS-mutant melanomas. In 
order to address the role of 
this protein in melanocytic 
migration, melanomagenesis, 
and PD-L1 expression, melanoma cell lines were created with varying LKB1 status. Immunoblot 
of human melanoma cell lines revealed that SK-MEL 103 cells are LKB1-deficient (Figure 2A). 
By contrast, SKMEL-147 cells are LKB1-proficient. Previous assays performed in our lab have 
also confirmed that both lines are heterozygous for a NRASQ61R mutation. In addition to these 
human melanoma cell lines,the murine lines NL212, NL216, and NL145, which were developed 
from tumors of TpLN mice (NRas-mutant, p16-deficient and Lkb1-deficient), were also chosen to 
A. 
 
 
 
 
 
B. 
Figure 2. Establishment of melanoma cell lines with differing LKB1 
status. A, Immunoblot of LKB1 in human melanoma cell lines. The 
SK-MEL 103 cell line is LKB1-deficient, whereas the SK-MEL 147 
line is LKB1-proficient. B, Immunoblot demonstrating the successful 
integration of lentiviruses encoding LKB1 and LKB1-KD (kinase dead) 
in three murine (NL212, NL216, NL145) and two human cell lines 
(SK-MEL 103 and SK-MEL 147).  Here, V = vehicle (Lkb1-null), L = 
LKB1-proficient, and K = LKB1 kinase-dead. Two distinct clones of 
NL212 were generated by separate lentiviral transductions, 
distinguished by Set #1 and Set #2.  
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study the role of LKB1. Infection and puromycin selection of NL212, NL216, NL145, SK-MEL 
103, and SK-MEL 147 cell lines with lentiviruses encoding either LKB1 or LKB1-KD resulted 
in the generation of stable cell lines (Figure 2B).  
 
Restoration of LKB1 inhibits cellular migration 
Migration assays were 
performed in NL212, 
NL216, and NL145 cells 
to evaluate the impact of 
LKB1 status on migratory 
potential (Figure 3A). As 
we hypothesized that the 
LKB1 tumor suppressor 
was important in 
preventing metastasis, we 
expected to see that cell 
lines with functional Lkb1 
would experience reduced 
migration, whereas cell lines 
with loss of Lkb1 would 
experience enhanced 
migration. Consistent with 
Figure 3. Restoration of LKB1 inhibits cellular migration. A, Diagram 
illustrating the protocol followed for wound healing assays. MMC 
represents mitomycin C treatment, employed to prevent cell proliferation 
during the assay. B, Area of wound and percent wound closure in three 
cell lines, NL212, NL216, and NL145, was measured using ImageJ 
software. Here, V = vehicle (Lkb1-null), LKB1 = LKB1-proficinet, and 
LKB1-KD = LKB1 kinase-dead. Two distinct clones of NL212 were 
produced by separate lentiviral transductions, distinguished by Set #1 and 
Set #2. Significance values are denoted by asterisks, with ** indicating P 
≤ 0.01 and **** indicating P ≤ 0.0001. All wound healing assays were 
performed in triplicate. C, Representative images of wound healing assays 
at T = 0 and T =18 for LKB1-deficient and –proficient cell lines.   
A. 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
C. 
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our hypothesis, results demonstrated that the introduction of LKB1 into the NL cells lines limits 
their migration (33.31% reduction in migration in NL212, 6.13% in NL216) (Figure 3B-C). A 
reduction in migration was not seen in the NL145 cell line. This could be partially explained by 
the Lkb1-null line’s intolerance to mitomycin C treatment, which may have influenced the 
migratory rate. In the NL212 cell line, introduction of LKB1-KD resulted in a partial limitation 
in migration (18.77%), though not as completely as when introduced with LKB1 (33.31%). 
Though consistent with the NL212 results, the NL216 results were much less dramatic; 
restoration of LKB1insignificantly limited migration (6.13%) and LKB1-KD migratory rates 
matched those of the LKB1-null. In the NL145 cell line, introduction of LKB1-KD dramatically 
increased migration (33.44%). Though variable among the NL cell lines, migration rates in 
LKB1-KD cell lines reveal that LKB1 kinase activity may be important, but not solely 
responsible for the reduction in cell motility.  
 
Restoration of kinase-deficient and –proficient LKB1 increases PD-L1 expression  
Several studies have implicated a potential relationship between LKB1 status and PD-L1 
expression in lung cancer, though one has yet to be established in melanoma. Should a 
relationship between LKB1 status and PD-L1 expression exist in melanoma, it is possible that 
LKB1 may be able to be used as a biomarker for response to immune checkpoint inhibitor 
therapies, such as PD-L1 inhibitors. For instance, if it is found that LKB1 regulates PD-L1, then 
it is possible that LKB1-null tumors would not respond to a PD-L1 inhibitor, as the inhibitor 
would not have a target. To investigate the potential for LKB1 as a biomarker for checkpoint 
inhibitor therapies, flow cytometry was employed to evaluate PD-L1 expression in murine 
melanoma cell lines with differing LKB1 status.  Across all lines, LKB1-null cells had low PD-
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L1 expression (<22%). With restoration of LKB1, PD-L1 expression increased in two of the 
three cell lines, though the amount varied by line (Figures 4A-B). The NL212 line showed the 
most significant change, with an average increase in PD-L1 expression of 57.7% when LKB1 
No antibody Isotype control Vehicle PD-L1 LKB1 PD-L1 LKB1-KD PD-L1
No antibody IsotypeControl
Vehicle
PD-L1
LKB1
PD-L1
LKB1-KD
PD-L1
NL212 0.20 ± 0.39 0.59 ± 0.60 3.56 ± 6.56 61.23 ± 27.89 27.55 ± 22.32
NL216 0.79 ± 0.34 0.592 ± 0.44 21.40 ± 11.99 7.00 ± 0.97 51.98 ± 27.78
NL145 0.49 ± 0.69 0.47 ± 0.54 4.67 ± 6.27 12.40 ± 8.34 30.90 ± 9.62
87.20.260 22.50.67
68.913.60.5 0.5 6.75
18.3 24.10.230 0.93
A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
Figure 4. Re-expression of LKB1-KD increases PD-L1 expression. A, Sample flow cytometry data for 
each murine cell line, demonstrating low levels of PD-L1 expression in all of the parental,  Lkb1-null lines 
(vehicle) and high PD-L1 expression in all LKB1-KD lines. Percentage of PD-L1 positive cells is indicated 
in the bottom right corner of each graph. B, Chart illustrating the average percentage of PD-L1-positive 
cells for each cell line, with standard deviations. Results were quantified using IDEAS software, with gates 
set so that isotype controls had ≤1% of cells marked positive. Five replicates were conducted in the NL212 
and NL216 cell lines; 3 replicates were conducted in the NL145 cell line.  
Norma
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was introduced; in the NL145 line, average PD-L1 expression increased 7.7%. In contrast, when 
LKB1 was restored in the NL216 line, PD-L1 expression decreased by 14.4%.  Across all lines, 
PD-L1 expression increased in LKB1-KD mutants (24.0% in NL212, 30.6% in NL216, and 
26.23% in NL145).  It is currently unclear why the loss of LKB1 kinase function but not total 
loss of LKB1 results in high PD-L1 levels. Further characterization of LKB1’s kinase activity is 
necessary. However, these results demonstrate that a relationship between LKB1 status and PD-
L1 expression may indeed exist, indicating that LKB1 has potential to serve as a biomarker for 
response to immune checkpoint inhibitor therapies.  
 
UV-exposed TpLNR mice develop melanoma more slowly than TpNR mice  
To confirm that LKB1 loss promotes metastasis both in vitro and in vivo, TpLNR mice, 
containing conditional knock-in (i.e. LSL-N-RasQ61R and Rosa26-YFP) and knock-out (i.e. p16L 
and LKB1L) alleles (Figure 5A), and TpNR mice, containing LSL-N-RasQ61R, Rosa26-YFP, and 
p16L alleles, were compared following exposure to UV radiation (Figure 5B). With regard to 
melanoma-free survival, TpNR mice developed melanomas first, at a median age of 5 weeks, 
whereas TpLNR mice developed melanomas at a median age of 8.43 weeks (Figure 5C). Upon 
sacrifice, average tumor burden was significantly higher in the TpNR mice (an average of 4.4 
tumors/ animal vs. 1.4 tumors/animal in TpLNR mice; Figure 5D), however, many of the TpLNR 
mice in the study are still young and have yet to develop melanomas. Tumors in the two cohorts 
of mice had similar tumor growth rates once established (Figure 5D). 
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 TpNR 4.5 kJ/m2 (n=19) TpLNR 4.5 kJ/m2 (n=16) TpLNR 0  kJ/m2 (n=7)  TpNR 4.5 kJ/m2 (n=11)  TpLNR 4.5 kJ/m2(n=16)    TpLNR 0  kJ/m2 (n=7) 
 
 
 
 
 
 
 
 
 
 
Figure 5. TpLNR mice exposed to UV radiation develop tumors more quickly than their non-exposed 
counterparts, but less quickly than TpNR mice.  A, Shown are schematics for the alleles used to generated 
TpLN
Q61R
-YFP lineage tracer mice. All mice in the present study carry the Tyr-CRE-ER
T2
 transgene and are 
homozygous for the p16
L
, LKB1
L
, LSL-N-rasQ61, and Rosa26-YFP alleles.  B, Timeline for CRE 
Recombinase activation and UV exposure. Mice were split into ultra-violet (UV) exposure and non-exposure 
groups at a 3:1 ratio.  C, Left, Kaplan-Meier curves showing that in TpLNR mice, median melanoma-free 
survival is higher than in TpNR mice (8.43 weeks vs. 5 weeks). Right, Kaplan-Meier curves showing the 
overall survival of TpLNR and TpNR mice.  D, Left, TpLNR mice exposed to UV radiation develop more 
tumors than their non-exposed counterparts, but develop fewer tumors than TpNR mice (an average of 1.4 
tumors/animal in TpLNR mice vs. an average of 4.4 tumors/ animal in TpNR mice); however, many of the TpLNR mice 
are still young and have yet to develop melanomas. Right, Growth rates of both spontaneous and UV-induced 
tumors in TpLNR mice, as measured by calipers.  
A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
C. 
 
 
 
 
 
 
 
 
 
 
D. 
 
B. 
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A. 
 
 
 
 
 
 
 
 
 
 
 
B. 
UV exposure promotes melanocytic hyperproliferation and macrometastases in TpLNR 
mice 
To evaluate the cooperation between 
LKB1 and UV radiation in the 
development of macrometastases, 
TpLNR mice were dissected following 
UV exposure and melanoma formation. In 
necropsies, UV-exposed TpLNR mice exhibit 
severe melanocytic hyperproliferation 
along their tails, ears, and paws, which is 
not observed in non-exposed counterparts 
(Figure 6A). UV-exposed mice also show 
pronounced evidence of macrometastases 
to the lymph node, spleen, liver, and brain 
(Figure 6B). These results mimic clinical 
findings, in which the most common sites of regional melanoma metastasis are lymph nodes and 
for distant metastasis are the skin, lung, brain, liver, bone, and intestine[20]. In other studies 
performed by our lab, TpNR mice, which maintain functional LKB1, have less evidence of 
macrometastases (<10%), with the most common observations being multiple secondary skin 
tumors and enlarged, darkened lymph nodes.  
 
 
Figure 6. TpLNR mice exposed to UV radiation show 
evidence of macrometastases and other melanocytic 
hyperplasia. A, Shown are typical phenotypes of the 
UV-exposed TpLNR animals. Top, An animal that has 
developed aggressive melanoma on its flank.  Bottom left, 
Example of melanocytic hyperproliferation on the paw, 
believed to be attributable to Lkb1 loss. Bottom center 
and right, Evidence of metastasis: enlarged, pigmented 
lymph nodes, pigmented spleen, lesions along one lobe of 
liver and a lesion on the frontal lobe of the brain.  B, 
Chart indicating the number of UV-exposed TpLNR 
mice with putative macrometastases in each organ type.  
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Discussion 
 
The role of LKB1 in migration 
Our work establishes that migration in murine melanoma cell lines is LKB1-dependent, and 
partially contingent on LKB1’s kinase function. However, there was high variability between 
cell lines with regard to the impact of LKB1 on migration. The three murine melanoma cell lines 
used in this study came from TpLN mice which harbor identical driver mutations (loss of the p16 
and LKB1 tumor suppressors as well as a Q61R mutation in the NRAS proto-oncogene); 
however, it is impossible to know which secondary mutations may have occurred to promote the 
development of the melanomas. These secondary mutations may play a role in the migratory 
ability of the cells and influence the impact of LKB1 reintroduction. Further characterization of 
each cell line will be necessary to understanding why LKB1 differentially alters the migratory 
potential of each line. Furthermore, as LKB1 plays a role in multiple signaling pathways, it is 
possible that changes in migratory rates in LKB1-deficient, LKB1-proficient, and LKB1-KD 
cells are attributable to altered expression of proteins downstream of LKB1, such as AMP-
activated protein kinase (AMPK). It will therefore be important to evaluate the impact of LKB1 
loss/reintroduction on multiple downstream proteins in each cell line. Finally, to provide further 
data on each cell line’s migratory potential, Boyden chamber migration assays could also be 
performed, and the results compared to the wound healing assay data. 
 
Drawbacks in the infection methods used may also provide a potential explanation for LKB1’s 
variable impact. The LKB1 and LKB1-KD viruses were not titered and therefore, infection rates 
in each cell line may differ. Inconsistent viral uptake within each cell line likely resulted in some 
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cells incorporating multiple copies of LKB1 while others incorporated very few. These 
inconsistencies could have profound impacts on not only the results of our migration assays, but 
also on ourflow cytometry findings. To ensure consistency in LKB1 expression for future 
experiments, it would be important to titer the virus prior to infection and to then form clonal 
populations within each cell line. To further assure similar LKB1 expression between cell lines, 
RT-PCR for LKB1 mRNA could be performed.  
 
Potential for LKB1 as a biomarker for checkpoint inhibitor therapies  
Our flow cytometry results reveal a potential relationship between LKB1 expression and PD-L1. 
Should these results prove true in future trials, this would lend support to the idea that patients 
with tumors harboring LKB1 deletions are not suitable candidates for immune checkpoint 
inhibitor therapies targeting the PD-1-PD-L1 interaction, unless LKB1 expression could be 
restored. These results differ from the previously mentioned lung cancer studies by Xu et al., 
where it was found that loss of LKB1 correlated with high PD-L1 levels[14]. This difference may 
be attributable to the multitude of pathways that regulate PD-L1 and the differing importance of 
each pathway in lung cancer versus melanoma. For example, one such pathway is the PI3K/Akt-
mTOR pathway, in which LKB1 is thought to inhibit the phosphorylation of mTOR, causing a 
downstream reduction in PD-L1 expression. Xu et al. found that this pathway in particular was 
heavily implicated in lung cancer[14]; in melanoma, however, the Ras-MAPK pathway, which 
also regulates PD-L1 expression, is more relevant[16] and may play a larger role in regulating 
PD-L1 expression, which could explain why the presence of LKB1 did not eliminate PD-L1 
expression. Future mechanistic studies are needed to determine why LKB1-KD is sufficient to 
restore PD-L1 expression. Our next step in elucidating LKB1-KD’s relationship with PD-L1 will 
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be to perform a co-immunoprecipitation to determine what exactly LKB1-KD is binding. As 
revealed by the standard deviations present in Figure 4B, there is high variability even between 
trials in each cell line. Optimization of protocols may be important moving forward, and it will 
also be crucial to complete more trials to gain reliable results. As mentioned earlier, greater 
consistency may be achieved by creating clonal populations to account for the amount of LKB1 
present in each cell line. Additionally, the relationship between LKB1 and PD-L1 in vivo should 
be examined by immunohistochemistry (IHC) in tumor samples from both the TpLNR (lacking 
LKB1) and TpNR models (containing functional LKB1).  
 
The TpLNR-UV mouse model as a genetically faithful model of human melanoma 
Though several metastatic melanoma mouse models exist today, many lack clinical relevance. 
As previously mentioned, some utilize RAS isoforms that are rarely observed in human 
melanomas[16], while others overexpress NRAS at super-physiological concentrations[17], 
reducing the ability to generalize results to human patients. The present study, however, has 
established a clinically-relevant, UV-induced NRAS-driven melanoma mouse model that allows 
for characterization of the role of LKB1 in metastasis in vivo. This model can be used to better 
establish the organs to which LKB1-null, NRAS-mutant melanomas metastasize and quantify the 
frequency of these metastases. Ultimately, this model will be invaluable for understanding 
metastases in melanoma and could provide a way to test future therapeutics.  
 
A major drawback to this mouse line is the inability to characterize micrometastases. Though 
analysis of organs during necropsy has made it is possible to observe large-scale metastatic 
lesions, it is highly likely that smaller micrometastases are occurring and go unnoticed. The 
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Rosa26-LSL-YFP allele incorporated in these mice, meant to enable visualization of melanocytes 
throughout the body, has proven unsuccessful.  While genotyping has confirmed that the allele is 
present in the mice, recent YFP staining and fluorescent microscopy of tissue samples has been 
incapable of detecting any YFP. At this time, we are uncertain whether the problem lies in the 
gene’s recombination, a problem with its insertion point, or something different altogether; 
therefore, this allele is currently insufficient in tracking melanocytes throughout the bodies of our 
mice. To ascertain whether there may be a problem in transcription of the gene, future 
experiments include evaluating YFP mRNA levels by performing RT-PCR on tumor samples; 
similarly, we will lyse tumor samples and perform an immunoblot for YFP to determine whether 
any YFP protein is present. Due the barriers we have met with this allele, we are presently 
working to introduce a different lineage tracer, Rosa26-LSL-LacZ, into our TpLN mice to 
provide more reliable detection of melanocyte-derived malignancies. Future studies with these 
mice will allow for more sensitive characterization of LKB1-related metastases in NRAS-driven 
melanomas.  
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